实用老年医学

实用老年医学 ›› 2024, Vol. 38 ›› Issue (4): 362-366.doi: 10.3969/j.issn.1003-9198.2024.04.009

• 临床研究 • 上一篇    下一篇

老年肝癌病人经肝动脉化疗栓塞术联合仑伐替尼治疗的疗效及安全性分析

孔杰, 姜锐, 刘正立, 何旭, 赵伯翔, 公茂峰, 王小平, 陆照璇, 顾建平, 张磊   

  1. 210006江苏省南京市,南京医科大学附属南京医院(南京市第一医院)普外科
  • 收稿日期:2023-06-20 发布日期:2024-04-23
  • 通讯作者: 张磊,Email:kilogram@163.com

Efficacy and safety of transcatheter arterial chemoembolization combined with lenvatinib in the treatment for hepatocellular carcinoma in elderly patients

KONG Jie, JIANG Rui, LIU Zhengli, HE Xu, ZHAO Boxiang, GONG Maofeng, WANG Xiaoping, LU Zhaoxuan, GU Jianping, ZHANG Lei   

  1. Department of General Surgery, Affiliated Nanjing Hospital of Nanjing Medical University (Nanjing First Hospital), Nanjing 210006, China
  • Received:2023-06-20 Published:2024-04-23
  • Contact: ZHANG Lei, Email: kilogram@163.com

PDF (PC)

458

摘要： 目的 比较肝动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)单独治疗和联合仑伐替尼治疗老年中晚期肝细胞肝癌(HCC)的临床疗效及安全性。 方法 收集2018年6月至2020年8月南京市第一医院老年HCC病人的临床资料,根据治疗方法分为TACE组63例和TACE联合仑伐替尼组(联合组)76例,比较2组病人的肿瘤应答情况、生存情况及不良反应发生率。 结果 联合组的客观缓解率(43.7%)和疾病控制率(60.1%)均显著高于TACE组的23.8%、38.1%(P<0.001)。TACE组和联合组病人的中位无疾病进展时间(PFS)分别为7.5和12.5个月;中位生存时间(OS)分别为9.6和15.8个月,差异均有统计学意义(P<0.05)。2组随访过程中的不良反应均为Ⅰ~Ⅱ度,经过对症处理均有效控制。 结论 在老年中晚期HCC病人中,TACE联合仑伐替尼治疗方案可显著提高疗效,延长生存期,并且安全性良好。

关键词: 经动脉化疗栓塞, 肝细胞肝癌, 仑伐替尼

Abstract: Objective To investigate the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib in the treatment for intermediate-to-advanced hepatocellular carcinoma (HCC) in the elderly patients. Methods The clinical data of the elderly HCC patients treated at Nanjing First Hospital from June 2018 to August 2020 were collected. All patients were divided into TACE group (n=63) and TACE plus lenvatinib group (n=76) according to treatment methods. The tumor response, survival outcomes, and adverse events were compared between the two groups. Results The Objective response rate (ORR) and disease control rate (DCR) were significantly higher in TACE plus lenvatinib group than those in TACE group (P<0.001). The median progression-free survival (PFS) was 7.5 months in TACE group, compared with 12.5 months in TACE plus lenvatinib group (P<0.05). The median overall survival (OS) was 9.6 months in TACE group, compared with 15.8 months in TACE plus lenvatinib group (P<0.05). The adverse events during follow-up were grade I-II and effectively controlled with symptomatic treatment. Conclusions In the elderly patients with intermediate-to-advanced HCC, the combination of TACE and lenvatinib can significantly improve efficacy and prolong survival time, and is well-tolerated.

Key words: transarterial chemoembolization, hepatocellular carcinoma, lenvatinib

中图分类号: